Embodiments relate to pharmaceutical compositions, comprising one or more beta-3 adrenoceptor agonists that are useful for the treatment of lower urinary tract symptoms such as, for example, overactive bladder, prostate disorders and methods for treating lower urinary tract symptoms utilizing the pharmaceutical compositions, comprising one or more beta-3 adrenoceptor agonists. In some embodiments, the pharmaceutical compositions, comprising one or more beta-3 adrenoceptor agonists comprise pulsatile drug delivery systems. Embodiments further relate to a dosing regimen, comprising beta-3 adrenoceptor agonists and anti-muscarinic agents that are both useful for the treatment of lower urinary tract symptoms; methods for treating lower urinary tract symptoms methods utilizing the dosing regimens, comprising beta-3 adrenoceptor agonists anti-muscarinic agents; and consumer packaging, comprising both beta-3 adrenoceptor agonists and anti-muscarinic agents packaged and arranged to ensure patient compliance.

Embodiments relate to pharmaceutical compositions, comprising one or more beta-3 adrenoceptor agonists that are useful for the treatment of lower urinary tract symptoms such as, for example, overactive bladder, prostate disorders and methods for treating lower urinary tract symptoms utilizing the pharmaceutical compositions, comprising one or more beta-3 adrenoceptor agonists. In some embodiments, the pharmaceutical compositions, comprising one or more beta-3 adrenoceptor agonists comprise pulsatile drug delivery systems. Embodiments further relate to a dosing regimen, comprising beta-3 adrenoceptor agonists and anti-muscarinic agents that are both useful for the treatment of lower urinary tract symptoms; methods for treating lower urinary tract symptoms methods utilizing the dosing regimens, comprising beta-3 adrenoceptor agonists anti-muscarinic agents; and consumer packaging, comprising both beta-3 adrenoceptor agonists and anti-muscarinic agents packaged and arranged to ensure patient compliance.

Provided are novel prodrugs of treprostinil, as well as methods of making and methods of using these prodrugs.

Provided are novel prodrugs of treprostinil, as well as methods of making and methods of using these prodrugs.

The present disclosure is directed to novel methods of treating type-1 or type-2 diabetes by inactivating TLR2 and TLR4 genes together in cells capable of producing insulin and/or regenerating β cells, and providing the cells to a subject in need thereof.

The present disclosure is directed to novel methods of treating type-1 or type-2 diabetes by inactivating TLR2 and TLR4 genes together in cells capable of producing insulin and/or regenerating β cells, and providing the cells to a subject in need thereof.

Provided are novel prodrug salts of selective aquaporin inhibitors, their use as pharmaceuticals, and pharmaceutical compositions comprising them, and novel processes for their synthesis and novel intermediates for use in their synthesis. Also provided is use of a compound for the prophylaxis, treatment, and control of aquaporin-mediated conditions. Aquaporin inhibitors, e.g., inhibitors of AQP4 and/or AQP2, may be of utility in the treatment or control of diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord), hyponatremia, and excess fluid retention, as well as diseases such as epilepsy, retinal ischemia and other diseases of the eye, myocardial ischemia, myocardial ischemia/reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines.

Provided are novel prodrug salts of selective aquaporin inhibitors, their use as pharmaceuticals, and pharmaceutical compositions comprising them, and novel processes for their synthesis and novel intermediates for use in their synthesis. Also provided is use of a compound for the prophylaxis, treatment, and control of aquaporin-mediated conditions. Aquaporin inhibitors, e.g., inhibitors of AQP4 and/or AQP2, may be of utility in the treatment or control of diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord), hyponatremia, and excess fluid retention, as well as diseases such as epilepsy, retinal ischemia and other diseases of the eye, myocardial ischemia, myocardial ischemia/reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines.

The present invention is directed to a composition including a Tryptophol derivative, a 4-Ethyl-Phenol derivative, or a combination thereof, and a method of using same, such as for treating a subject in need of modulation of blood coagulation.

The present invention is directed to a composition including a Tryptophol derivative, a 4-Ethyl-Phenol derivative, or a combination thereof, and a method of using same, such as for treating a subject in need of modulation of blood coagulation.